复发或难治性惰性B细胞和套细胞淋巴瘤患者接受苯达莫司汀治疗后出现持续性淋巴细胞减少。
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
作者信息
Saito H, Maruyama D, Maeshima A M, Makita S, Kitahara H, Miyamoto K, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Taniguchi H, Tobinai K
出版信息
Blood Cancer J. 2017 Nov 3;7(11):e620. doi: 10.1038/bcj.2017.100.
Abstract
This corrects the article DOI: 10.1038/bcj.2015.86.
摘要
这更正了文章的数字对象标识符
10.1038/bcj.2015.86 。
相似文献
1
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.复发或难治性惰性B细胞和套细胞淋巴瘤患者接受苯达莫司汀治疗后出现持续性淋巴细胞减少。
Blood Cancer J. 2017 Nov 3;7(11):e620. doi: 10.1038/bcj.2017.100.
2
Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.复发或难治性惰性B细胞和套细胞淋巴瘤患者接受苯达莫司汀治疗后出现长期淋巴细胞减少。
Blood Cancer J. 2015 Oct 23;5(10):e362. doi: 10.1038/bcj.2015.86.
3
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.苯达莫司汀联合利妥昔单抗与氟达拉滨联合利妥昔单抗治疗复发惰性和套细胞淋巴瘤患者的比较：一项多中心、随机、开放标签、非劣效性 3 期临床试验。
Lancet Oncol. 2016 Jan;17(1):57-66. doi: 10.1016/S1470-2045(15)00447-7. Epub 2015 Dec 5.
4
Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.盐酸苯达莫司汀联合利妥昔单抗治疗复发或难治性侵袭性 B 细胞非霍奇金淋巴瘤的可行性和药代动力学研究。
Cancer Sci. 2011 Sep;102(9):1687-92. doi: 10.1111/j.1349-7006.2011.01994.x. Epub 2011 Jul 7.
5
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.苯达莫司汀的发现和发展用于治疗非霍奇金淋巴瘤。
Expert Opin Drug Discov. 2016 Nov;11(11):1123-1130. doi: 10.1080/17460441.2016.1233174. Epub 2016 Sep 16.
6
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.苯达莫司汀联合利妥昔单抗与 CHOP 联合利妥昔单抗作为惰性和套细胞淋巴瘤患者一线治疗的比较：一项开放标签、多中心、随机、3 期非劣效性临床试验。
Lancet. 2013 Apr 6;381(9873):1203-10. doi: 10.1016/S0140-6736(12)61763-2. Epub 2013 Feb 20.
7
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.苯达莫司汀联合利妥昔单抗治疗复发惰性B细胞和套细胞非霍奇金淋巴瘤的II期多中心研究
J Clin Oncol. 2008 Sep 20;26(27):4473-9. doi: 10.1200/JCO.2008.17.0001. Epub 2008 Jul 14.
8
Bendamustine's emerging role in the management of lymphoid malignancies.苯达莫司汀在淋巴恶性肿瘤治疗中的新作用。
Semin Hematol. 2011 Apr;48 Suppl 1:S24-36. doi: 10.1053/j.seminhematol.2011.03.004.
9
Pharmacokinetic profile and first preliminary clinical evaluation of bendamustine in Taiwanese patients with heavily pretreated indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.苯达莫司汀在台湾经过大量预处理的惰性B细胞非霍奇金淋巴瘤和套细胞淋巴瘤患者中的药代动力学特征及首次初步临床评估。
Hematol Oncol. 2015 Dec;33(4):136-44. doi: 10.1002/hon.2161. Epub 2014 Aug 11.
10
Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.苯达莫司汀联合利妥昔单抗治疗复发/难治性套细胞淋巴瘤的II期研究：疗效、耐受性及安全性结果
Ann Hematol. 2015 Dec;94(12):2025-32. doi: 10.1007/s00277-015-2478-9. Epub 2015 Sep 28.
引用本文的文献
1
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma.阿基仑赛作为滤泡性/边缘区淋巴瘤患者的一种治疗选择的作用。
Ther Adv Hematol. 2021 May 29;12:20406207211017788. doi: 10.1177/20406207211017788. eCollection 2021.
2
Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study.含利妥昔单抗方案治疗的非霍奇金淋巴瘤患者骨髓样本中造血前体细胞的动力学：一项流式细胞术研究
Int J Hematol. 2015 Jul;102(1):59-66. doi: 10.1007/s12185-015-1798-9. Epub 2015 May 8.
Zotero 插件